Ollie Whittome

[Ollie Whittome @MrLukaku]

@benjames1996 Beautiful scenes

[Ollie Whittome @MrLukaku]

@Kwamegh13 @Footballtweet

[Ollie Whittome @MrLukaku]

@angelperezpx Good, all scum

[Ollie Whittome @MrLukaku]

@7_pistcs @rkhargreaves @footballontnt He was also rubbing his cock tbf

[Ollie Whittome @MrLukaku]

@footballtweet Show the table?

[Ollie Whittome @MrLukaku]

@nathanshort1 😂

[Ollie Whittome @MrLukaku]

Now we have VAR can we bring this back please? @UEFAcom

[Ollie Whittome @MrLukaku]

@nathanshort1 @harryfromRSP The game that had it all, hope that fella was found alive and well after he went missing 8 minutes in

[Ollie Whittome @MrLukaku]

@theepopprince It's dead man get over it

[Ollie Whittome @MrLukaku]

@ScottDaley26 Because football is shit nowadays and laughable.

[Ollie Whittome @MrLukaku]

@RickyBo17401513 @leesenior13 @dubslife1 😂😂😂

[Myles McNulty @MylesMcNulty]

This is possibly the most consequential RNS that @avacta #AVCT has ever put out.

"Our first program, AVA6000, demonstrates a four- to six-fold increase in the therapeutic index in the clinic and in preclinical models.... We are now seeing a 75-fold increase in therapeutic index with our recently announced exatecan program, AVA6103 in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic."

- the maximum tolerated dose of pre|CISION exatecan (AVA6103) observed is 75 times that of conventional exatecan in a daily dosing regimen;

- up to 50-fold higher warhead concentrations in the tumor versus plasma in a patient-derived xenograft model;

- AVA6103 inhibits tumor growth, with complete responses noted in a preclinical treated model (N.B. multiple CRs!).

This drug will obliterate the existing competition in the ADC space (notably, the currently market-leading Enhurtu and Trodelvy ADCs that use Top-1 inhibitors). And I don't mean just surpass; but properly obliterate.

The company has nailed the science and the platform now. It can be used to harness immensely toxic warheads - the most potent in existence; and can be used to target as much as three quarters of all cancer cases worldwide.

A truly transformational development in the field of oncology.

The UK market may not see it immediately (especially given immediate-term Budget concerns and silly games over the HCI bond), but the world of Big Pharma will.

I am convinced that Avacta will be acquired within 12 months now - possibly much sooner.

[Michael Morelli @morellifit]

This is Thomas Seyfried.

He's a scientist who's dedicated 30+ years to researching cancer.

His message? Cancer IS preventable.

It's caused by lifestyle factors, not genetics.

Here are Seyfried's 7 MOST important rules for preventing cancer:

[Ollie Whittome @MrLukaku]

@SkyNews What am I mean to do? Swim up to it, and start harassing it?

[Leeds United @LUFC]

🥶 Light work

[Ollie Whittome @MrLukaku]

A great milestone, well done #AVCT

[Avacta @avacta]

Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study. https://t.co/cwBrCnWo1s #AVCT

[Ollie Whittome @MrLukaku]

@FootyScran @FCUnitedMcr I got heartburn just seeing this

[Ollie Whittome @MrLukaku]

@matty_boiii @SkyNews Nice

[Aaron Ray Hermes 🦅🇺🇸 @realAaronHermes]

@elonmusk Woke AI is so hot right now.

[Ollie Whittome @MrLukaku]

@ChelseaFC Annonce Ryan Babel